CLX vs RNA · P/E 15, rev $7.10B vs rev $22.6M
The Clorox Company (CLX) versus Atrium Therapeutics, Inc. Common Stock (RNA) — a side-by-side from cached financials, not a winner call.
The Clorox Company (CLX) is a household & personal products company listed on US.
Atrium Therapeutics, Inc. Common Stock (RNA) is a biotechnology company listed on NASDAQ.
Latest reported CLX revenue for 2025-06-30 was $7.10B. Net income was $824.0M. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
Latest reported RNA revenue for 2026-06-30 was $22.6M. Net income was -$36.8M. Revenue was up 15.3% from 2026-03-31 to 2026-06-30. RNA currently screens at market cap $217.5M.
CLX currently screens at market cap $10.89B and trailing P/E 14.6. RNA currently screens at market cap $217.5M.
Not investment advice. Open the CLX and RNA stock pages for the full models.
Not investment advice.